8-K filed Jun 16, 2026 at 08:46 ET
Outlook Therapeutics announced FDA acceptance of its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) to treat wet AMD. The FDA classified the resubmission as a Class 1 review with a 60-day review period, setting a PDUFA goal date of July 29, 2026. This moves the company one step closer to potential U.S. approval for its ophthalmic bevacizumab formulation, which already has marketing authorization in the EU and UK.